Cognitive Function in a Randomized Trial of Evolocumab

Cited by (493)

Items 401–493 of 493

1. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
   Angela Pirillo, Lale S Tokgözoğlu, Alberico Luigi Catapano · 2023 · European Atherosclerosis Journal
2. Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future
   Alessandro Sciahbasi, Paola Russo, Michela Zuccanti, L Chiorazzo, F Castelli, Antonino Granatelli · 2024 · Journal of Clinical Medicine
3. Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial
   Britta S. Bürker, K. Englund, C.M. Østby, Stein Andersson, Lars Lysgaard Gullestad, Kaspar Broch · 2025 · Clinical Transplantation
4. Accidente isquémico transitorio tras espaciar la dosis de alirocumab: ¿es recomendable reducir las dosis de iPCSK9 ante c-LDL muy bajos?
   Sandra Piqueras Ruiz, Alejandro Parra‐Virto, Ana Torres do Rego, Pablo Demelo Rodríguez, José Luis Álvarez-Sala · 2019 · Clínica e Investigación en Arteriosclerosis
5. Statin-Associated Muscle Symptoms Are Real
   Peter Paul Toth · 2020 · Contemporary cardiology
6. Low cholesterol syndrome and drug development
   Ahmed Handhle, Adie Viljoen, Radha Ramachandran, Anthony S. Wierzbicki · 2020 · Current Opinion in Cardiology
7. Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias
   José Tuñón, Ana María Pello Lázaro, Marta López‐Castillo, Álvaro Aceñaa · 2020 · Revista Española de Cardiología Suplementos
8. Sztatin- és nem sztatinkészítmények az LDL-koleszterin-szint csökkentésében : Változások az elmúlt évtizedben
   László Gerő · 2022 · Diabetologia Hungarica
9. Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
   Solenne Vigne, Donovan Duc, Yannick Yersin, Jessica Rebeaud, Florian Ruiz, Benjamin Peter, Tinh‐Hai Collet, Caroline Pot · 2021 · Research Square
10. Future Energy Supply, Simulations with Limited Resources
    Léo Benichou · 2011 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
11. PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications
    Wang, Jia Dong James, Teo, Andrea York Tiang, Xiao, Bin, Chao, Yinxia, Zhou, Zhi Dong, Tan, Brendan Jen-Wei, Chan, Ling-Ling, Rosalie, Elvira, Tan, Eng-King · 2026 · Translational Neurodegeneration
12. No effect of PCSK9 inhibitors on cognitive function
    Irene Fernández-Ruíz · 2017 · Nature Reviews Cardiology
13. Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
    Laura H. Waite, Yvonne L. Phan, Sarah A. Spinler · 2017 · Annals of Pharmacotherapy
14. Kognition leidet nicht unter LDL-C-Senkung
    HC Diener · 2017 · MMW - Fortschritte der Medizin
15. The final word about LDL-cholesterol lowering
    Dan A. Streja · 2018 · Current Opinion in Endocrinology Diabetes and Obesity
16. Nuevos enfoques farmacológicos para el riesgo cardiovascular
    Pilar Mazón‐Ramos · 2018 · Medicina Clínica
17. The year in cardiology 2017: prevention
    Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2018 · Cardiologia Croatica
18. New pharmacological approaches for cardiovascular risk
    Pilar Mazón‐Ramos · 2018 · Medicina Clínica (English Edition)
19. Letter by Koh Regarding Article, “PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)”
    Kwang Kon Koh · 2018 · Circulation
20. Hyperlipidämie: Welche Rolle spielen PCSK9-Inhibitoren?
    Dirk Meyer, Martin Merkel · 2018 · DMW - Deutsche Medizinische Wochenschrift
21. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke
    David Sullivan, Paul Bonnitcha, Catherine Spinks, Tony Keech · 2018 · Circulation Genomic and Precision Medicine
22. PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape
    Enrique Morales-Villegas, Kausik Kumar Ray · 2019 · Frontiers in cardiovascular drug discovery
23. Emerging Lipid-Lowering Therapies in Secondary Prevention
    Dhruv Mahtta, Salim S. Virani, Anthony A. Bavry · 2019 · Current Cardiovascular Risk Reports
24. Editorial commentary: Using PCSK9 inhibitors to win at “cholesterol limbo”
    Paul D. Thompson · 2019 · Trends in Cardiovascular Medicine
25. Nuevas perspectivas en el tratamiento de la hipercolesterolemia desde la disponibilidad de los inhibidores de la proteína PCSK9
    Xavier Pintó, Itziar Sarasa · 2019 · Hipertensión y Riesgo Vascular
26. Novel Therapies for Dyslipidemia
    Olta Tafaj-Reddy · 2019 · IntechOpen eBooks
27. Evolución en el manejo de las dislipemias: análisis comparativo de las guías ESC 2019 versus ACC/AHA 2018
    Sánchez Vega, Juan Diego, Zamorano Gómez, José Luis · 2019 · Revista Uruguaya de Cardiología
28. Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?
    Sandra Piqueras Ruiz, Alejandro Parra‐Virto, Ana Torres do Rego, Pablo Demelo Rodríguez, José Luis Álvarez-Sala · 2020 · Clínica e Investigación en Arteriosclerosis (English Edition)
29. Modernes Lipid-Management
    Thomas F. Lscher, Augusto Gallino, Laurent Haegeli, Richard Kobza, Konstantinos C. Koskinas, A. Miserez, David Nanchen, Georg Noll, Giovanni Battista Pedrazzini, Lorenz Rber et al. · 2020 · Cardiovascular Medicine
30. Niedriges LDL-C ohne Effekt auf die Kognition
    Springer Medizin · 2017 · InFo Neurologie + Psychiatrie
31. ESC-Leitlinie Dyslipidämien: die 10 Kernbotschaften
    Kai Toussaint, Claudia Brückner · 2020 · MMW - Fortschritte der Medizin
32. Comments on the most important and recent studies involving PCSK9i
    R Češka · 2018 · Vnitřní lékařství
33. The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
    Ronak Rengarajan, Kristen M. Tecson, Peter Andrew McCullough · 2020 · Contemporary cardiology
34. PCSK9-Inhibitoren - Erfahrungen im klinischen Alltag
    Ursula Kassner, Tim Hollstein · 2020 · CardioVasc
35. New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
    Ahmed Bakillah · 2019 · MDPI eBooks
36. Guideline recommendations, clinical trial data, and new and emerging therapies
    John Lindsley · 2021 · The American Journal of Managed Care
37. Finalement, jusqu’où faut-il baisser le LDL-cholestérol et comment ?
    Sophie Béliard · 2021 · Médecine des Maladies Métaboliques
38. Therapy and clinical trials
    Klaus Georg Parhofer · 2018 · Current Opinion in Lipidology
39. Eficacia del tratamiento con evolocumab en pacientes con cardiopatía isquémica
    Edgar Gustavo Ramos-Martínez, Laura Perez-Campos Mayoral, Marco Antonio Hernández-Mercado, Juan Carlos Ramos-Martínez · 2021 · Cardiovascular and Metabolic Science
40. PCSK9 Inhibiting Monoclonal Antibodies
    Zain V. Ahmed, Prerak V. Juthani, Megan L. Lee, Nihar R. Desai · 2021 · Stroke revisited
41. New Agents for Treatment of Dyslipidemia
    V. Simha · 2021 · Clinical Dilemmas in Diabetes
42. Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial
    Chamithra D Rupasinghe, Theodosios Kantas, Rohail Sani, Natalia M Avendaño Capriles, Ramil Dadabhoy, Afreenish Gul, Camilo Andrés Avendaño Capriles, Noman Khurshid Ahmed, Sohaib Tousif · 2021 · Cureus · Retracted
43. Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung
    Franz‐Josef Neumann · 2019 · Deutsches Ärzteblatt
44. Current approaches to cardiovascular risk management in patients with ischemic stroke. (Press-Release) Proceedings of the Symposium on October 28, 2021 at the Interregional Scientific-Practical Conference with International Participation "Stroke: an Interdisciplinary Problem
    Redaktsiia · 2021 · S S Korsakov Journal of Neurology and Psychiatry
45. Drugs That Affect Lipid Metabolism
    Rebecca J. C. Tran, Kerry Anne Rambaran · 2018 · Side effects of drugs annual
46. Gender-specific association between unidirectional variation of cholesterol and cognitive decline: a longitudinal study of middle-aged and elderly adults
    Huamin Liu, Rui Zhou, Jiazhen Zheng, Minyi Zhang, Keyi Wu, Zhiwei Huang, Zelin Yuan, Xian-Bo Wu · 2021 · Research Square
47. Commentary to "Perioperative care in open aortic vascular surgery: A consensus statement by the Enhanced Recovery After Surgery (ERAS) Society and Society for Vascular Surgery"
    Álvaro Torres Blanco · 2023 · Angiología
48. Commentary to "How to Treat Peripheral Arteriovenous Malformations"
    Eliseo Candela · 2023 · Angiología
49. A FOURIER-OLE – Evidencia a hosszú távon fennálló igen alacsony LDL-koleszterin-szint kedvező hatásáról
    László Márk · 2023 · Cardiologia Hungarica
50. Treatment Guidelines Overview
    Alberico Luigi Catapano · 2023 · Elsevier eBooks
51. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
    Nicholas Marston, Marc Steven Sabatine · 2023 · Elsevier eBooks
52. CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
    Adilson Boson Almeida, Claudina Mendes Horevicht · 2023 · EPITAYA eBooks
53. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and residual risk
    Ángel Alberto García-Peña, Luz Clemencia Zárate-Correa, Claudia Monsalve · 2023 · Revista Colombiana de Cardiología
54. Place des inhibiteurs du PCSK9 dans le traitement des hypercholestérolémies
    Cécile Yelnik · 2024 · La Presse Médicale Formation
55. A Retrospective Study: The Effectiveness of Lipid-Lowering Medications in Individuals at High Risk for Cardiovascular Disease
    Fethullah Kayan, Serhat Günlü · 2024 · Dicle Medical Journal / Dicle Tip Dergisi
56. A Comprehensive Review and Prospects on the Impact of Lipid-Lowering Drugs on Cognitive Functions
    立君 韩 · 2024 · Advances in Clinical Medicine
57. How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?
    Tian Chen, Naifeng Liu · 2024 · Current Opinion in Lipidology
58. Low LDL, High Reassurance? Evolocumab’s Long-Term Cognitive Safety Profile
    Katarina Zorcic, Sudeep S. Gill · 2024 · NEJM Evidence
59. Use of Lipid-Lowering Agents and Therapeutic Goal Achievement in Cardiovascular High- Risk Patients in Argentina
    Alan Rodrigo Sigal, Melisa Antoniolli, Pilar López Santi, Nicolás Aquino, Ezequiel D. Lerech, Fernando O. Botto · 2021 · Revista Argentina de Cardiología
60. Advances in peptide-based drug discovery
    Bhavesh Khatri, João Paulo Linhares Velloso, Shambhawi, Meng‐Wei Kan, David J. Craik · 2025 · Elsevier eBooks
61. Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed
    Artur Dziewierz, Beata Bobrowska, Witold Streb, Francesco Pelliccia, Stanisław Bartuś, Renata Rajtar-Salwa · 2025 · Expert Review of Cardiovascular Therapy
62. Understanding sex differences in LDL-C and cardiovascular risk
    Mücahit Yetim, Abdülmelik Bi̇rgün, Macit Kalçık · 2025 · Journal of clinical lipidology
63. Protocolo de prevención primaria y secundaria de la cardiopatía isquémica
    B. Álvarez Álvarez, Jesús Martinón Martínez, R.M. Agra Bermejo, Diego Iglesias-Álvarez, P. Rigueiro Veloso, José María García‐Acuña, José Ramón González‐Juanatey · 2025 · Medicine - Programa de Formación Médica Continuada Acreditado
64. Cardiovascular Protective Effects of PCSK9 Inhibitors and Research Progress in Their Application for Heart Failure Treatment
    静 谭 · 2025 · Advances in Clinical Medicine
65. Cardiovascular Disease and Risk Management
    2025 · American Diabetes Association eBooks
66. Von Kräutern zu Pillen, Biologics und Nukleinsäuren
    Thomas Felix Lüscher, Arnold von Eckardstein, Jürg Hans Beer, Lorenz Räber, Isabella Sudano, David Nanchen, Christian Eugen Mueller, François Mach, Ulf Landmesser · 2022 · Cardiovascular Medicine
67. Document de Consensus Sur la Prise en Charge du Cholestérol LDL
    François Mach, Augusto Gallino, Laurent Haegeli, Richard Kobza, Konstantinos C. Koskinas, André R. Miserez, David Nanchen, Giovanni Battista Pedrazzini, Lorenz Räber, Isabella Sudano et al. · 2022 · Cardiovascular Medicine
68. Additional file 1 of An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence
    Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, Nik Newland · 2024 · Figshare
69. Additional file 1 of An impact of lipid profile and lipid lowering drugs on ≥70 year olds of an upper socioeconomic class: a retrospective cohort study
    Yehudit Eden-Friedman, Steinberg, David M., Michal Canetti, Cohen, Ido, Shlomo Segev, Ophira Salomon · 2021 · Figshare
70. New insights into the treatment of hyperlipidemia: An expert review
    Brian Tomlinson · 2026 · 童綜合醫學雜誌
71. CARotid plaqUe StabilizatiOn and regression with evolocumab: the CARUSO Study
    Tiziana Claudia Aranzulla, Andrea Gaggiano, Simone Quaglino, Salvatore Endrio Oleandri, Rita D' Aniello, Salvatore Piazza, Marco Pavani, Fabrizio Delnevo, Claudia De Natale, Giuseppe Musumeci · 2026 · medRxiv
72. Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting
    Giuseppe Nasso, Walter Vignaroli, Giuseppe Santarpino, Claudio Larosa, Isabella Rosa, Francesco Bartolomucci, Vincenzo Montemurro, Flavio Fiore, Antongiulio Valenzano, Giacomo Errico et al. · 2026 · Frontiers in Cardiovascular Medicine
73. Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia
    Brian Tomlinson · 2026 · Expert Opinion on Pharmacotherapy
74. Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes
    Julia Brandts, Kausik Kumar Ray · 2026 · Elsevier eBooks
75. Genetic causes of cardiovascular disease : special focus on familial hypercholesterolemia and thoracic aortic aneurysms
    Sandy Elbitar · 2018 · theses.fr (ABES)
76. Hypercholestérolémie familiale : recherche de nouveaux gènes et étude des formes polygéniques
    Youmna Ghaleb · 2017 · theses.fr (ABES)
77. Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review
    Dominique Stéphan, Camille Zamperini, Elena‐Mihaela Cordeanu · 2026 · International Journal of Cardiology Cardiovascular Risk and Prevention
78. Manejo práctico de la terapia hipolipemiante en el ictus y ataque isquémico transitorio: consenso y recomendaciones prácticas
    María del Mar Freijo, P. Cardona, Mar Castellanos, R. de Torres-Chacón, A. Gil-Núñez, M. Guillán, Patricia Martínez‐Sánchez, Enrique Jesús Palacio-Portilla, F. Purroy, Tomás Segura et al. · 2026 · Neurología
79. Consensus statement and clinical recommendations on the practical management of lipid-lowering therapy in stroke and transient ischaemic attack
    Marimar Freijo-Guerrero, Pere Cardona, Mar Castellanos, Reyes de Torres-Chacón, A. Gil-Núñez, Marta Guillán, Patricia Martínez-Sánchez, Enrique Jesús Palacio-Portilla, Francisco F. Purroy, Tomás Segura et al. · 2026 · Neurología (English Edition)
80. A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention
    L. Masana, Josep Ribalta, Daiana Ibarretxe · 2026 · The Lancet Diabetes & Endocrinology
81. PCSK9 inhibitors do not increase cognitive risk
    Dongsheng Ni, Zeying Feng, Dehuan Liang, Zhaolai Qi, Yao Lu, Liyong Zhu, Guoping Li · 2026 · Biology Direct
82. PCSK9 as an Emerging Target for Cerebrovascular Dysfunction and Neuroinflammation in Ischemic Stroke
    C Emperatriz Ramirez Salazar De Vela, Josephin Wagner, Pál Pacher, Falk W. Lohoff · 2026 · ACS Chemical Neuroscience
83. Evolocumab in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis of efficacy and safety
    Sha Li, Cuigai Zhang, Yanping Liu · 2026 · BMC Cardiovascular Disorders
84. From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium
    Andrej Belančić, Josip A. Borovac · 2026 · Journal of Cardiovascular Pharmacology and Therapeutics
85. Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials
    Vikash Jaiswal, Novonil Deb, Fakhar Latif, abhigan babu Shrestha, Vamsi Garimella, Nishat Shama, Sahas Reddy Jitta, Sidra Naz, Tushar Kumar, Shazia Khan et al. · 2026 · The American Journal of Medicine
86. Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
    Andrew M. Carlson, Zaid A. Zayyad, Stefanie Driesenga, Peter Boxley, Atreya Mishra, Omar Uraizee, Rediat Ephrem, Runze Zhang, Zachary Natsheh, Adhir Ramesh Shroff · 2026 · Cardiology and Therapy
87. Potential Reach of First Oral PCSK9 Inhibitor Could Be a ‘Major Advance’ for Hypercholesterolemia
    Gina Shaw · 2026 · Neurology Today
88. Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment
    Ahmed Talkhan, Mohamed Hamouda Elkasaby, Ahmed S. A. Osman, Muhammad M. Elsharkawy, Mohammad Shehata, kareem ahmed khalefa, Ahmed Mohamed Seleim, Amr M. Abou Elezz, William H. Fishman, Wilbert S. Aronow · 2026 · Cardiology in Review
89. Safety and tolerability of nonstatin LDL-cholesterol-lowering therapies: A systematic review and pairwise meta-analysis of randomized controlled trials
    Andrea Matteucci, Michela Bonanni, Stefania Angela Di Fusco, Alessandro Aiello, Stefano Aquilani, Silvio Fedele, Federico Nardi, Furio Colivicchi · 2026 · Journal of clinical lipidology
90. Comparative efficacy of Traditional Chinese Medicine classical prescriptions for angina pectoris: a network meta-analysis
    Hai-Yi Liang, Xinyu Ji, Si-Qi Liu, Shu-Han Zhao, Fu-Yi Yang, Bai Du, Shuai Shi · 2026 · Frontiers in Pharmacology
91. BindingDB Entry 50008625: Small molecules as inhibitors of PCSK9: Current status and future challenges.
    BindingDB · 2021 · UC San Diego
92. Emerging Computational Advances in Simulating PCSK9 Variant Dynamics for Therapeutic Design Against Hypercholesterolemia
    María Cecilia Opazo, Andrés Gallegos, Antar Muñoz, Roger Zapata, Juan Carlos Rivera, Romina V. Sepúlveda, Daniel Aguayo · 2026 · International Journal of Molecular Sciences
93. PCSK9 inhibitor use and risk of dementia and neurodegenerative diseases in adults aged 50 Years and older: a global electronic health record study
    Shuo-Yan Gau, Shao‐Wei Lo, CHRISTINE HSU, Yung-Fang Tu, Yu-Jung Su, Chien-Chin Chen, Meng-Che Wu, Yasue Mitsukura, Hui-Chin Chang · 2026 · Frontiers in Pharmacology